TIGIT and intrahepatic cholangiocarcinoma: In another phase I trial, A Japanese patient with advanced ICC received four cycles of combined therapy with atezolizumab (anti-PD-1 inhibitor) and tiragolumab (anti-TIGIT inhibitor), demonstrating better tolerability and antitumor activity (PFS: 2.8 months) [56].